160,500 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Bought by Springhill Fund Asset Management HK Co Ltd

Springhill Fund Asset Management HK Co Ltd acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 160,500 shares of the company’s stock, valued at approximately $3,024,000. Nurix Therapeutics comprises 4.9% of Springhill Fund Asset Management HK Co Ltd’s investment portfolio, making the stock its 12th biggest holding.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. US Bancorp DE lifted its holdings in shares of Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares during the last quarter. Quarry LP boosted its holdings in shares of Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Nurix Therapeutics during the 4th quarter valued at $209,000. EP Wealth Advisors LLC bought a new stake in Nurix Therapeutics in the third quarter worth $240,000. Finally, EntryPoint Capital LLC purchased a new position in Nurix Therapeutics during the fourth quarter worth $266,000.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $9.69 on Friday. The company’s 50-day simple moving average is $15.45 and its 200-day simple moving average is $19.89. Nurix Therapeutics, Inc. has a fifty-two week low of $9.45 and a fifty-two week high of $29.56. The stock has a market capitalization of $738.73 million, a P/E ratio of -3.35 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 5,825 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the sale, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $488,660.76. The trade was a 14.73 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares of the company’s stock, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,326 shares of company stock valued at $213,449 over the last ninety days. Company insiders own 7.20% of the company’s stock.

Wall Street Analyst Weigh In

NRIX has been the subject of several analyst reports. BTIG Research initiated coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 target price for the company. Morgan Stanley boosted their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, February 3rd. Leerink Partners began coverage on Nurix Therapeutics in a report on Monday, March 17th. They issued a “market perform” rating and a $16.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Nurix Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC cut their price objective on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Three equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.88.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.